Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

41. Tenofovir reduces mother-to-child hepatitis B transmission

Tenofovir reduces mother-to-child hepatitis B transmission Tenofovir reduces mother-to-child hepatitis B transmission Discover Portal Discover Portal Tenofovir reduces mother-to-child hepatitis B transmission Published on 25 July 2017 doi: Giving pregnant women with hepatitis B the drug tenofovir reduced the likelihood of passing the infection on to their baby by about 80% and did not have any adverse impact on mother or child. Hepatitis B often doesn't cause any obvious symptoms in adults (...) and typically passes in a few months without treatment, but in children it often persists for years and may cause progressive liver damage with cirrhosis and increased risk of liver cancer. Babies can get the infection from their mother during birth. The findings of this systematic review support current NICE recommendations that pregnant women with active hepatitis B infection are treated in the third trimester using the drug tenofovir and at risk babies immunised after birth. Share your views

2019 NIHR Dissemination Centre

42. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. (PubMed)

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO's

Full Text available with Trip Pro

2019 Lancet

43. Acetyl-L-carnitine for patients with hepatic encephalopathy. (PubMed)

Acetyl-L-carnitine for patients with hepatic encephalopathy. Hepatic encephalopathy is a common and devastating neuropsychiatric complication of acute liver failure or chronic liver disease. Ammonia content in the blood seems to play a role in the development of hepatic encephalopathy. Treatment for hepatic encephalopathy is complex. Acetyl-L-carnitine is a substance that may reduce ammonia toxicity. This review assessed the benefits and harms of acetyl-L-carnitine for patients with hepatic (...) encephalopathy.To assess the benefits and harms of acetyl-L-carnitine for patients with hepatic encephalopathy.We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, LILACS, and Science Citation Index Expanded for randomised clinical trials. We sought additional randomised clinical trials from the World Health Organization Clinical Trials Search Portal and ClinicalTrials.gov. We performed all electronic searches until 10 September 2018. We looked through

2019 Cochrane

44. Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes - GOV.UK GOV.UK uses cookies to make the site simpler. Search Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes Monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first (...) 3 months of treatment, and modify diabetes medication or doses when necessary. Patients with diabetes may experience symptomatic hypoglycaemia if diabetic treatment is continued at the same dose due to potential for an enhanced hypoglycaemic effect. Published 18 December 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: rapid reduction in hepatitis C viral load during direct-acting antiviral therapy for hepatitis C may lead to improvements in glucose metabolism

2019 MHRA Drug Safety Update

45. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA SCIENTIFIC AD VICE www.ecdc.europa.eu Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approachECDC SCIENTIFIC ADVICE Public health guidance on HIV, hepatitis B and C testing in the EU/EEA An integrated approach ii This guidance was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Andrew J Amato-Gauci and Lara Tavoschi with the support of Helena (...) Kingdom Masoud Dara, World Health Organization (WHO) Regional Office for Europe, Denmark Michael Ninburg, World Hepatitis Alliance, United Kingdom Mika Salminen, National Institute for Health and Welfare, Finland Mojca Maticic, University Medical Centre Ljubljana, Slovenia Nikos Dedes, EATG/Positive Voice, Greece Peter Vickerman, University of Bristol, United Kingdom Philippa Easterbrook, WHO, Switzerland Raj Patel, IUSTI/NHS England, United Kingdom Ruta Kaupe, DIA+LOGS, Latvia Slim Fourati, European

2019 European Centre for Disease Prevention and Control - Public Health Guidance

46. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA

Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA Suggested citation: European Centre for Disease Prevention and Control. Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Stockholm, December 2018 Reproduction is authorised, provided the source is acknowledged. PDF Print ISBN 978-92-9498-291-9 ISBN 978-92-9498-292-6 DOI 10.2900/809892 DOI 10.2900/579896 Catalogue number TQ-06-18-361-EN-N (...) Catalogue number TQ-06-18-361-EN-C © European Centre for Disease Prevention and Control, Stockholm, 2018 Scope and purpose of guidance The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. Figure 1. The case for integrated

2019 European Centre for Disease Prevention and Control - Public Health Guidance

47. A meta-analysis and systematic review of the literature regarding HBV reactivation with the use of direct-acting antiviral agents in the treatment of hepatitis C, and HBV reactivation with use of anti-TNF agents, and any correlation with anti-hepatitis B

A meta-analysis and systematic review of the literature regarding HBV reactivation with the use of direct-acting antiviral agents in the treatment of hepatitis C, and HBV reactivation with use of anti-TNF agents, and any correlation with anti-hepatitis B Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

48. The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation

The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

49. The efficacy and safety of glucocorticoids plus conventional therapy for hepatitis B-related liver failure in China: a meta-analysis

The efficacy and safety of glucocorticoids plus conventional therapy for hepatitis B-related liver failure in China: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

50. The efficacy of two different dosages of hepatitis B immunoglobulin in interrupting mother-to-infant transmission of hepatitis B virus: a systematic review and meta-analysis

The efficacy of two different dosages of hepatitis B immunoglobulin in interrupting mother-to-infant transmission of hepatitis B virus: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

51. The effect of antiviral treatment discontinued post partum for pregnant women with chronic hepatitis B viral infection: a systematic review and network meta-analysis

The effect of antiviral treatment discontinued post partum for pregnant women with chronic hepatitis B viral infection: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

52. The rate of significant histological disease in immune tolerant phase among people with chronic hepatitis B virus infection: a systematic review and meta-analysis

The rate of significant histological disease in immune tolerant phase among people with chronic hepatitis B virus infection: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

53. The effect of microvascular anastomosis on hepatic artery thrombosis in paediatric liver transplantation: a systematic review and meta-analysis

The effect of microvascular anastomosis on hepatic artery thrombosis in paediatric liver transplantation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

54. Tobacco smoking and hepatitis C virus infection: burden, joint health effects and opportunities for the treatment of both

Tobacco smoking and hepatitis C virus infection: burden, joint health effects and opportunities for the treatment of both Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

55. Systematic review and network analysis: the efficacy and safety of antiviral therapy for hepatitis B infection during different trimesters of pregnancy

Systematic review and network analysis: the efficacy and safety of antiviral therapy for hepatitis B infection during different trimesters of pregnancy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

56. Role of non-invasive assessment of liver fibrosis in predicting liver-related events in chronic viral hepatitis patients: a systematic review and meta-analysis

Role of non-invasive assessment of liver fibrosis in predicting liver-related events in chronic viral hepatitis patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

57. A simplified scoring system for the diagnosis of autoimmune hepatitis: a systematic review and meta-analysis

A simplified scoring system for the diagnosis of autoimmune hepatitis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

58. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia

An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

59. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with non-alcoholic fatty liver disease: a systematic review

The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with non-alcoholic fatty liver disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

60. Proton pump inhibitor therapy and the risk of hepatic encephalopathy in cirrhotic patients

Proton pump inhibitor therapy and the risk of hepatic encephalopathy in cirrhotic patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO